Efforts for new chelators

[bernstein]

Hi Folks,

have found an interesting link about chelation.

Does anyone knows something about deferitrin or Starch-DFO.

Its good that there are continous researches. So all of us get a chance for good iron chelatation.

https://www.nyas.org/ebriefreps/prin...ntEbriefID=387

[Vik]

Bernstein - link not working :(
could you repost?

[bernstein]

Ok, try with this link:

http://www.nyas.org/ebriefreps/main....sectionID=2704

if this dosen't work try it with

http://www.nyas.org/cooleys

Than go to "meeting report" and click on "chelators"

Hope this works

[Vik]

cool!

• Deferitrin (GT56-252) is in development by Genzyme. A Phase I study of the study has been completed.

• Starch-DFO (S-DFO, 40SD02) is in development by Biomedical Frontiers. The phase I study has been completed.

[bernstein]

Originally Posted by Vik

cool!

• Deferitrin (GT56-252) is in development by Genzyme. A Phase I study of the study has been completed.

• Starch-DFO (S-DFO, 40SD02) is in development by Biomedical Frontiers. The phase I study has been completed.

This is what i've found about deferitrin:

http://www.icoc-isocam.org/icoc/abstractbook.pdf.

Look at page 31

As i know there are some trials in many hospitals of Italy and also in Whittington hospital of London.

[Narendra]

From:- http://www.cooleysanemia.com/bodies/body356.php

August 6, 2007 - An article recently published in the British Journal of Haematology provides an update on the iron chelator 40SD02, (starch-conjugating deferoxamine (S-DFO), often referred to as “Starch Desferal”).

The article, entitled “Phase 1b clinical trial of starch-conjugating deferoxamine (40SD02): a novel long-acting iron chelator,” details the results of a single-dose trial conducted in 2002 and 2003 at Children’s Hospital Oakland and Weill Medical College of Cornell University/New York-Presbyterian Hospital.

Unlike regular deferoxamine, which is typically administered subcutaneously for an 8-12 hour period, 5-7 nights per week, Starch Desferal is designed to be administered intravenously for a shorter period of time and at significantly greater intervals, thereby providing a chelation option that maximizes potential for compliance. For this study, the drug was administered only one time, for one hour. Study subjects did not receive another dose or any other chelating agents for the one week they were involved in the trial.

16 individuals with beta-thalassemia were enrolled in and completed the trial. Four different dose levels – 150 mg/kg, 300 mg/kg, 600 mg/kg and 900 mg/kg – were tested, with four patients assigned to each level. (900 mg/kg is equivalent to 237 mg/kg of regular deferoxamine.)

Starch Desferal, which is created by attaching deferoxamine to a modified starch polymer, was found to be safe and well-tolerated within the parameters of this study. Four of the patients experienced a skin disruption(hives),which was judged as either mild or moderate.

The authors of the study concluded that “a single 60-minute infusion of S-DFO stimulated prolonged urinary iron excretion extending over several days. Mean 7-day urinary iron excretion (in mg elemental iron excreted per kg body weight) in the highest dose group (900 mg/kg) was 1.31 (range 0.79-1.93) mg/kg.” Although there was considerable variability in excretion between patients (as is often the case with other chelating agents), there did appear to be a linear dose-response relationship between the amount of drug given and the amount of iron excreted.

The authors suggest that some complications related to thalassemia may be closely related to non-transferrin bound iron (NTBI) in the blood and therefore that “…the presence of continuous chelating capacity in the circulation may be beneficial. S-DFO appears to provide such protection in a dose-dependent fashion with excess free iron-binding capacity in the circulation for more than 6 days, on average, in the high-dose group.”

Further studies are necessary to determine whether this period of excess chelating capacity in the plasma can be extended with repeat dosing and whether other measures support these initial results. The authors also suggested that “if continuous chelating capacity in the circulation can be maintained, S-DFO may be useful in ‘combined therapy’ intended to promote additive or synergistic excretion.”

The effect of S-DFO on stool iron excretion was not examined in this trial.

This study was sponsored by Biomedical Frontiers, Inc., a private biopharmaceutical company which is developing 40SD02.

[Vik]

very interesting.